PVEK (IMGN632)
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 30 patients (estimated)
- Sponsors
- Fred Hutchinson / University of Washington Cancer Consortium
- Collaborators
- ImmunoGen, Inc.
- Tags
- Antibody Drug Conjugate (ADC), CD123
- Trial Type
- Treatment
- Last Update
- 10 months ago
- SparkCures ID
- 1869
- NCT Identifier
- NCT06034470
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.